Literature DB >> 23260669

Induction of CD8+ regulatory T cells protects macaques against SIV challenge.

Wei Lu1, Song Chen, Chunhui Lai, Weizhong Guo, Linchun Fu, Jean-Marie Andrieu.   

Abstract

Efforts to develop a vaccine against HIV have so far met with limited success. Given that CD4(+) T cell activation drives the initial burst of viral replication, we explored in macaques whether an oral vaccine comprised of Lactobacillus plantarum, a commensal bacterium that favors immune tolerance, and inactivated simian immunodeficiency virus mac239 (SIVmac239) would induce CD4(+) T cell unresponsiveness/tolerance toward SIV antigens and thereby prevent the establishment of SIV infection. The tolerogenic vaccine induced MHC-Ib/E-restricted CD8(+) regulatory T cells (Tregs) that suppressed SIV-harboring CD4(+) T cell activation and ex vivo SIV replication in 15 of 16 animals without inducing SIV-specific antibodies or cytotoxic T lymphocytes. Of 16 macaques that were intrarectally challenged with SIVmac239 or heterologous strain SIVB670, 15 were sterilely protected. In four macaques that were rechallenged intravenously, plasma SIV levels peaked slightly and then dropped to undetectable levels, although the animals subsequently harbored intracellular SIV DNA. Infusion of CD8 antibodies confirmed the role of CD8(+) Tregs in preventing/suppressing SIV in vivo. These findings suggest a new avenue of research toward developing an HIV-1 vaccine.
Copyright © 2012 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23260669     DOI: 10.1016/j.celrep.2012.11.016

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  25 in total

Review 1.  HIV-1 vaccines: challenges and new perspectives.

Authors:  Jean-Louis Excler; Merlin L Robb; Jerome H Kim
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

2.  The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?!

Authors:  Vladimir Temchura; Matthias Tenbusch
Journal:  Virol Sin       Date:  2014-02       Impact factor: 4.327

3.  Intragastric Administration of Lactobacillus plantarum and 2,2'-Dithiodipyridine-Inactivated Simian Immunodeficiency Virus (SIV) Does Not Protect Indian Rhesus Macaques from Intrarectal SIV Challenge or Reduce Virus Replication after Transmission.

Authors:  Diane G Carnathan; Joseph J Mackel; Shelby L Sweat; Chiamaka A Enemuo; Etse H Gebru; Pallavi Dhadvai; Sailaja Gangadhara; Sakeenah Hicks; Thomas H Vanderford; Rama R Amara; José Esparza; Wei Lu; Jean-Marie Andrieu; Guido Silvestri
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

4.  Vaccination with Live Attenuated Simian Immunodeficiency Virus (SIV) Protects from Mucosal, but Not Necessarily Intravenous, Challenge with a Minimally Heterologous SIV.

Authors:  Matthew S Sutton; Charles M Burns; Andrea M Weiler; Alexis J Balgeman; Andrew Braasch; Gabrielle Lehrer-Brey; Thomas C Friedrich; Shelby L O'Connor
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

5.  Genetic disruption of CD8+ Treg activity enhances the immune response to viral infection.

Authors:  Tobias A W Holderried; Philipp A Lang; Hye-Jung Kim; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

6.  Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.

Authors:  Jose R Castillo-Mancilla; Amie Meditz; Cara Wilson; Jia-Hua Zheng; Brent E Palmer; Eric J Lee; Edward M Gardner; Sharon Seifert; Becky Kerr; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

7.  Divergent immunomodulating effects of probiotics on T cell responses to oral attenuated human rotavirus vaccine and virulent human rotavirus infection in a neonatal gnotobiotic piglet disease model.

Authors:  Kuldeep S Chattha; Anastasia N Vlasova; Sukumar Kandasamy; Gireesh Rajashekara; Linda J Saif
Journal:  J Immunol       Date:  2013-08-05       Impact factor: 5.422

8.  Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge.

Authors:  Chris A R Baker; Louise Swainson; Din L Lin; Samson Wong; Dennis J Hartigan-O'Connor; Jeffrey D Lifson; Alice F Tarantal; Joseph M McCune
Journal:  Sci Transl Med       Date:  2015-08-12       Impact factor: 17.956

9.  Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Authors:  Samir K Lakhashe; Siddappa N Byrareddy; Mingkui Zhou; Barbara C Bachler; Girish Hemashettar; Shiu-Lok Hu; Francois Villinger; James G Else; Shannon Stock; Sandra J Lee; Diego A Vargas-Inchaustegui; Egidio Brocca Cofano; Marjorie Robert-Guroff; Welkin E Johnson; Victoria R Polonis; Donald N Forthal; Erwann P Loret; Robert A Rasmussen; Ruth M Ruprecht
Journal:  Vaccine       Date:  2014-09-20       Impact factor: 3.641

Review 10.  Role of regulatory T cells during virus infection.

Authors:  Tamara Veiga-Parga; Sharvan Sehrawat; Barry T Rouse
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.